New Synthetic Antifungal Agents – K20 and Azole-based Fungicides

Technical Summary

•  Dr. Tom Chang and Dr. Jon Takemoto of Utah State University’s Chemistry/Biochemistry and Biology departments have developed a kanamycin derivative (K20) antifungal compound that, when paired with widely used azole fungicides, exhibits synergistic inhibitory effects against crop fungal pathogens including azole resistant strains.

•  K20 is a derivative of the aminoglycoside antibiotic kanamycin.  K20 is distinguished from the parent molecule kanamycin A by the presence of functional groups terminating in either an alkyl or phenyl group in the 6 position of ring III.  A preferred embodiment of the K20/azole combinations is the treatment of fungal disease in a host wherein azole resistance is problematic.


Commercial Applications

•  May be used in clinical settings for fungal treatment in humans and non-human mammals (exhibits considerable activity against Candida species in candidiasis)

•  May be used in crop protection settings (exhibits considerable activity against Fusarium crop disease pathogens (e.g. head scab))

•  May be administered through spraying, direct injection, topical application, oral administration, or by inclusion to the water supply

•  Potential commercial partners:

•  Pharmaceutical companies

•  Medical and chemical supply companies

•  Agrichemical companies

•  Crop protection suppliers


Competitive Advantages

•  K20 may be paired with most triazole and imidazole fungicides for synergistic effects

•  K20 production is scalable and derived from abundantly available kanamycin A

•  Novel mechanism of action

•  Low toxicity and environmentally friendly

•  Strong synergy can significantly reduce overuse of fungicides


Additional Information



Illustration of kill curves of itraconazole and K20 synergistic inhibition of Candida albicans ATCC 10231





•  US2014/0256665


Related Technologies

•  New Synthetic Antifungal Agents – K20 and Related Components (P10039)

•  New Synthetic Antifungal Agents – Variations to kanamycin A, kanamycin B, and tobramycin (P14062)


Patent Information: